KLRS
Kalaris Therapeutics Inc
$10.46
%
Analyst Rating:N/A

Stock Details

CEO

Andrew Oxtoby

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

14

Address

139 Main Street, Suite 500, Cambridge, MA, 02142

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Income Statement  

Financials

Selected Year

Revenue Estimates

EPS Estimates

Net Income Estimates

Price target for Kalaris Therapeutics Inc  $10.46

EPS

Revenue

Congress Tracker 

Insider Trading of Key Employees

Financial News: KLRS